Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 997

1.
2.
3.

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.

Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Mayzell G, Spyropoulos AC.

Clin Ther. 2004 Jul;26(7):1149-59.

PMID:
15336480
5.

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.

Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

J Manag Care Pharm. 2012 Jun;18(5):363-74.

6.

Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.

Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ.

Value Health. 2005 May-Jun;8(3):191-200.

7.

Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.

LaMori JC, Shoheiber O, Mody SH, Bookhart BK.

Clin Ther. 2015 Jan 1;37(1):62-70. doi: 10.1016/j.clinthera.2014.10.024. Epub 2014 Dec 15. Erratum in: Clin Ther. 2015 Oct 1;37(10):2382-3.

PMID:
25524389
8.

Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.

Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Pharmacoeconomics. 2014 Mar;32(3):305-13. doi: 10.1007/s40273-014-0131-4.

PMID:
24500859
9.

Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.

Kahler ZP, Beam DM, Kline JA.

Acad Emerg Med. 2015 Jul;22(7):796-802. doi: 10.1111/acem.12713. Epub 2015 Jun 25.

10.

The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.

Jugrin AV, Ustyugova A, Urbich M, Lamotte M, Sunderland T.

Thromb Haemost. 2015 Oct;114(4):778-92. doi: 10.1160/TH14-12-1027. Epub 2015 Aug 13.

PMID:
26272227
11.

Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.

Huse DM, Cummins G, Taylor DC, Russell MW.

Am J Manag Care. 2002 Jan;8(1 Suppl):S10-6.

12.

All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.

Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI.

J Manag Care Pharm. 2011 Nov;17(9):672-84.

13.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

15.

Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M.

J Manag Care Spec Pharm. 2015 Oct;21(10):965-72.

16.

Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.

Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC.

Thromb Haemost. 2012 Aug;108(2):291-302. doi: 10.1160/TH12-03-0162. Epub 2012 Jun 28.

PMID:
22739656
17.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Thromb Res. 2015 Feb;135(2):303-10. doi: 10.1016/j.thromres.2014.11.024. Epub 2014 Dec 4.

18.

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A.

Haematologica. 2007 Feb;92(2):199-205.

20.

Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.

MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J.

Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S5-15.

PMID:
17032933

Supplemental Content

Support Center